CSE:AGN - Post Discussion
Post by
StockHawk1 on Mar 24, 2023 7:22pm
AGN's DMT studies
The phara-development company Algernon Pharmaceuticals (AGN.c AGNPF) is helping to pave the way in psychdelic medicine by studying if DMT can help patients with brain injuries. The company is doing this through 2 studies.
This first study (which is currently ongoing) has the goal of determining if DMT can help post-stroke patients. AGN is currently dosing healthy patients to define a safe and non-psychedelic dose of DMT. In the next phase of this study, AGN will give the determined safe dose to stroke survivors to study if/how it improves their brain health.
AGN has also planned a similar study which will examine if DMT can aid those with Traumatic Brain Injuries (TBI). The company is hoping to use data from its stroke study (such as the determined safe DMT dose) to expidite this study.
For more information, you can check out AGN's website here: https://algernonpharmaceuticals.com/
Be the first to comment on this post